STOCK TITAN

Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aktis Oncology, Inc. director Ken Herrmann reported a same-day option exercise and sale. He exercised 3,065 stock options at $0.0800 per share into 3,065 shares of common stock, then sold 3,065 shares at a weighted average price of $25.2067, with individual trades between $25.00 and $25.4950. The exercised options were fully vested, and 3,506 options from this award remained outstanding, expiring November 23, 2030.

Positive

  • None.

Negative

  • None.
Insider Herrmann Ken
Role Director
Sold 3,065 shs ($77K)
Approx. gross sale proceeds $77K
Approx. exercise cost $245.20
Approx. pre-tax spread $77K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F2 3,065 $0.00 $0.00
Exercise Common Stock 3,065 $0.08 $245.20
Sale Common Stock F1 3,065 $25.2067 $77K
Holdings After Transaction: Stock Option (Right to Buy) — 3,506 shares (Direct); Common Stock — 0 shares (Direct)
Footnotes (2)
  1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.4950, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. These options have vested in full.
Options exercised 3,065 shares Stock options exercised into common stock on July 17, 2026
Option exercise price $0.0800 per share Exercise price for the 3,065 stock options converted to common stock
Shares sold 3,065 shares Common stock sold on July 17, 2026 following option exercise
Weighted average sale price $25.2067 per share Average price for 3,065 common shares sold in multiple transactions
Sale price range $25.00–$25.4950 per share Range of individual trade prices for the 3,065 shares sold
Remaining options after transaction 3,506 options Stock options beneficially owned following the reported exercise
Option expiration date November 23, 2030 Expiration date for the stock option award involved in the exercise
Stock Option (Right to Buy) financial
"security_title is reported as Stock Option (Right to Buy)"
weighted average price financial
"The price reported is a weighted average price. These shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description states Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
derivative exercise/conversion financial
"transaction_action is listed as derivative exercise/conversion"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Ken Herrmann report for AKTS?

Director Ken Herrmann reported a same-day option exercise and sale involving 3,065 Aktis Oncology, Inc. (AKTS) shares. He exercised stock options at $0.0800 per share into 3,065 common shares and then sold all 3,065 shares at a weighted average price of $25.2067.

How many Aktis Oncology (AKTS) shares did Ken Herrmann sell?

Ken Herrmann sold 3,065 shares of Aktis Oncology common stock. The sale followed his exercise of 3,065 stock options and was executed at a weighted average price of $25.2067 per share, according to the Form 4 filing details.

At what prices were AKTS shares sold in Ken Herrmann’s Form 4?

The reported sale used a weighted average price of $25.2067 per share. Footnote disclosure states the 3,065 shares were sold in multiple transactions at prices ranging from $25.00 to $25.4950, and detailed trade breakdowns are available on request.

What was the exercise price and size of Ken Herrmann’s AKTS option exercise?

Herrmann exercised 3,065 stock options for Aktis Oncology common stock at an exercise price of $0.0800 per share. These options were fully vested at the time of exercise, and the exercise generated 3,065 common shares that were then sold the same day.

When do Ken Herrmann’s remaining Aktis Oncology stock options expire?

After the reported transaction, Herrmann held 3,506 stock options from this award, which expire on November 23, 2030. The Form 4 shows this remaining derivative position as of the transaction date following the 3,065-option exercise.

Was Ken Herrmann’s AKTS trade reported under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not describe any trading plan. Based on this disclosure, the reported 3,065-share sale is not identified as occurring under a Rule 10b5-1 plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Herrmann Ken

(Last)(First)(Middle)
C/O AKTIS ONCOLOGY, INC.
17 DRYDOCK AVENUE, SUITE 17-401

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/17/2026M3,065A$0.083,065D
Common Stock07/17/2026S3,065D$25.2067(1)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.0807/17/2026M3,065 (2)11/23/2030Common Stock3,065$03,506D
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.4950, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. These options have vested in full.
/s/ Kyle D. Kuvalanka, as Attorney-in-Fact07/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)